The expression of NIS and Tg was significantly increased in the groups treated with SOR and ATRA, suggesting that the re-differentiation of thyroid cancer cells may be beneficial for antitumor therapy. The gene discussed is SLC5A5; the disease is thyroid gland carcinoma.